Concord Drugs Ltd
BSE:538965
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
C
|
Concord Drugs Ltd
BSE:538965
|
808.5m INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
948.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.6B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
224.1B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.2B EUR |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Concord Drugs Ltd
Glance View
Concord Drugs Ltd. engages in the provision of pharmaceutical formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-02-23. The firm is engaged in manufacturing of licensed drugs based on the formulations approved. The firm offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder). The firm also provides ready-to-fill pellets and multiple unit pellets system (MUPS). Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, nutrition and food supplement drug pellets, anti cholesterol drug pellets. The company also provides Iso Amyl 2-Cyano Acrylate, which is a bio-adhesive product.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Concord Drugs Ltd is 0.9%, which is below its 3-year median of 1.3%.
Over the last 3 years, Concord Drugs Ltd’s Net Margin has decreased from 2.1% to 0.9%. During this period, it reached a low of -1% on Sep 30, 2024 and a high of 3.9% on Sep 30, 2023.
